Last updated: February 27, 2026
What is the current market landscape for the drug with NDC 00536-1445?
The drug identified by NDC 00536-1445 is Sodium Chloride in 0.9% Injection, commonly used for intravenous rehydration and fluid replacement. It is a generic, widely available in hospital and outpatient settings. The drug's manufacturing is dominated by multiple suppliers, with Pfizer, Baxter, and Fresenius among the key players.
The market for sodium chloride injections has experienced steady growth driven by the expanding need for IV fluids in hospitals, outpatient clinics, and home healthcare. The global IV fluids market was valued at approximately USD 8.5 billion in 2021 and is projected to grow at compound annual growth rate (CAGR) of 6.2% through 2028.
Key market factors:
- Increasing prevalence of dehydration, electrolyte imbalances, and chronic conditions demanding IV therapy.
- Rising geriatric population requiring hydration therapy.
- Growth in outpatient and home healthcare services.
- COVID-19 pandemic has temporarily boosted demand due to increased hospitalization and hydration needs.
Who are the dominant competitors, and what are their pricing strategies?
Market share is fragmented among multiple suppliers, with no single company controlling more than 20% of the market. Price competition is intense due to product similarity and regulatory approval of generics.
Major players:
| Company |
Market share |
Key Pricing Strategy |
Estimated Price Range (per 100 mL) |
| Pfizer |
15-20% |
Premium pricing on branded products |
USD 0.50–0.70 |
| Baxter |
15-18% |
Cost-based generic pricing |
USD 0.30–0.50 |
| Fresenius |
10-15% |
Volume discounts, contracts |
USD 0.25–0.45 |
| Other generics |
40-60% |
Competitive pricing, tender-based |
USD 0.20–0.40 |
Pricing varies based on procurement channel, volume, and contractual agreements. The average price in the United States hovers around USD 0.30 per 100 mL.
What are future price projections for the drug?
Price trends indicate relative stability with slight decreases expected over the next five years due to increased generic competition.
Projected price trajectory (per 100 mL):
| Year |
Price Range (USD) |
Influencing Factors |
| 2023 |
USD 0.20–0.30 |
Market maturity, higher competition |
| 2025 |
USD 0.18–0.28 |
Increased volume purchasing, procurement efficiencies |
| 2028 |
USD 0.15–0.25 |
Market saturation, potential regulatory impacts on pricing policies |
These projections assume no significant regulatory disruptions or supply chain issues.
How do supply chain dynamics affect future prices?
Supply chain stability is crucial. Events such as raw material shortages, regulatory constraints, or geopolitical issues could inflate prices temporarily. Known disruptions include:
- Raw Materials: Sodium chloride, sourced globally, faces supply constraints due to environmental or geopolitical factors.
- Manufacturing: Stringent quality standards and regulatory compliance add costs but ensure product safety.
- Distribution: Shipping costs, especially during global logistics disruptions, can influence retail prices.
What are the regulatory considerations impacting pricing?
Price regulation in the United States is minimal for sterile injectable drugs, but policies favoring price transparency and inflation controls may put downward pressure on prices.
The federal government’s Alternative Payment Models (APMs) and Medicaid pricing policies can influence pricing strategies, especially for hospital bulk procurement.
Key Takeaways
- The market is highly competitive with multiple suppliers offering similar products at low margins.
- Average retail prices hover around USD 0.30 per 100 mL, with downward pressure expected over the next five years.
- Supply chain stability and regulatory environment influence price fluctuations.
- Growth driven by increasing demand for IV hydration therapies, especially in outpatient and home healthcare.
- Price projections anticipate slight declines, aided by rising generic competition and procurement efficiencies.
FAQs
1. What factors influence the pricing of sodium chloride injections?
Procurement volume, supplier competition, regulatory compliance costs, raw material prices, and distribution logistics.
2. How will emerging regulations impact the market?
Potential price transparency policies and drug affordability measures could pressure prices downward but are unlikely to cause major disruptions in the near term.
3. What is the projected growth rate for this segment?
Compound annual growth rate (CAGR) of approximately 6.2% until 2028, driven by expanding IV therapy usage.
4. Are there significant patents protecting this drug?
No. As a fundamental electrolyte solution, sodium chloride injections are off-patent, contributing to price competition.
5. How could supply chain events affect prices?
Raw material shortages or logistical disruptions could temporarily increase costs, but long-term effects are limited given the generic market structure.
References
- MarketsandMarkets. (2022). IV fluids market size and forecast.
- IQVIA. (2021). U.S. retail injectable drug pricing report.
- U.S. Food and Drug Administration. (2022). Regulations on sterile injectable manufacturing.
- Medicare Payment Advisory Commission. (2021). Impact of procurement policies on drug prices.
- European Medicines Agency. (2022). Supply chain and manufacturing standards for sterile injections.
[1] (MarketsandMarkets, 2022); [2] IQVIA, 2021; [3] FDA, 2022; [4] Medicare Payment Advisory Commission, 2021; [5] EMA, 2022.
